Bioventus (BVS) Net Cash Flow (2020 - 2026)

Bioventus (BVS) has reported Net Cash Flow for 7 consecutive years, with -$6.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow fell 160.76% year-over-year to -$6.0 million; the trailing twelve-month figure through Jun 2026 stood at -$2.2 million (down 217.7% YoY), and the FY2025 full-year result was $9.3 million, up 29.35% from the prior year.
• Net Cash Flow climbed to -$6.0 million in Q2 2026 per BVS's latest filing, from -$14.8 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $17.0 million in Q2 2023 and bottomed at -$41.4 million in Q3 2022.
• Historically, Net Cash Flow has averaged -$3.0 million across 5 years, with a median of -$2.9 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Net Cash Flow slumped 583.78% in 2022, then surged 1465.85% in 2025.
• Over 5 years, Net Cash Flow stood at -$3.6 million in 2022, then surged by 371.59% to $9.8 million in 2023, then sank by 94.15% to $571000.0 in 2024, then soared by 1465.85% to $8.9 million in 2025, then tumbled by 167.32% to -$6.0 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$6.0 million, -$14.8 million, and $8.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.